Ceftolozane–tazobactam- and ceftazidime–avibactam-resistant Pseudomonas aeruginosa mastoiditis

References

1. Peleg AY, Hooper DC. Hospital-Acquired infections due to gram-negative bacteria. N Engl J Med 2010; 362:1804–1813 [View Article]
   [Google Scholar]
2. Pang Z, Raudonis R, Glick BR, Lin T-J, Cheng Z. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Biotechnol Adv 2019; 37:177–192 [View Article]
   [Google Scholar]
3. van Duin D, Bonomo RA. Ceftazidime/Avibactam and Ceftolozane/tazobactam: second-generation β-lactam/β-lactamase inhibitor combinations. Clin Infect Dis 2016; 63:234–241 [View Article]
   [Google Scholar]
4. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 2009; 22:582–610 [View Article]
   [Google Scholar]
5. Bush K, Bradford PA. β-Lactams and β-Lactamase Inhibitors: An Overview. Cold Spring Harb Perspect Med 2016; 6:a025247 [View Article]
   [Google Scholar]
6. Meletis G, Exindari M, Vavatsi N, Sofianou D, Diza E. Mechanisms responsible for the emergence of carbapenem resistance in Pseudomonas aeruginosa . Hippokratia 2012; 16:303–307
   [Google Scholar]
7. Sorbera M, Chung E, CW H, Marzella N. Ceftolozane/tazobactam: a new option in the treatment of gram-negative infections. PT 2014; 39:828–832
   [Google Scholar]
8. Temkin E, Torre-Cisneros J, Beovic B, Benito N, Giannella M et al. Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms. Antimicrob Agents Chemother 2017; 61:e01964–16 [View Article]
   [Google Scholar]
9. Alatoom A, Elsayed H, Lawlor K, AbdelWareth L, El-Lababidi R et al. Comparison of antimicrobial activity between Ceftolozane-Tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa . Int J Infect Dis 2017; 62:39–43 [View Article]
   [Google Scholar]
10. Sader HS, Castanheira M, Shortridge D, Mendes RE, Flamm RK. Antimicrobial activity of ceftazidime-avibactam tested against multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa isolates from U.S. medical centers, 2013 to 2016. Antimicrob Agents Chemother 2017; 61: [View Article]
    [Google Scholar]
11. MacVane SH, Pandey R, Steed LL, Kreiswirth BN, Chen L. Emergence of ceftolozane-tazobactam-resistant Pseudomonas aeruginosa during treatment is mediated by a single AmpC structural mutation. Antimicrob Agents Chemother 2017; 61:e01183–17 [View Article]
    [Google Scholar]
12. Gangcuangco LM, Clark P, Stewart C, Miljkovic G, Saul ZK. Persistent bacteremia from Pseudomonas aeruginosa with In Vitro resistance to the novel antibiotics ceftolozane-tazobactam and ceftazidime-avibactam. Case Rep Infect Dis 2016; 2016:1520404 [View Article]
    [Google Scholar]
13. Wi YM, Greenwood-Quaintance KE, Schuetz AN, Ko KS, Peck KR et al. Activity of ceftolozane-tazobactam against carbapenem-resistant, non-carbapenemase-producing Pseudomonas aeruginosa and associated resistance mechanisms. Antimicrob Agents Chemother 2018; 62:e01970–17 [View Article]
    [Google Scholar]
14. Nguyen L, Garcia J, Gruenberg K, MacDougall C. Multidrug-Resistant Pseudomonas infections: hard to treat. but hope on the horizon? Curr Infect Dis Rep 2018; 20:23
    [Google Scholar]
15. Papp-Wallace KM, Zeiser ET, Becka SA, Park S, Wilson BM et al. Ceftazidime-avibactam in combination with fosfomycin: a novel therapeutic strategy against multidrug-resistant Pseudomonas aeruginosa . J Infect Dis 2019; 220:666–676 [View Article]
    [Google Scholar]
16. Clinical Laboratory Standards Insitute M100 Performance Standards for Antimicrobial Susceptibility Testing 10, 29th Edition. 2018
    [Google Scholar]